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Accelerated Death Benefits, Viatical Settlements,
and Viatical Loans: Options for the Terminally III
Paula Schmidt*

Abstract t
There are three options available for terminally ill insureds who are interested in accessing all or part of the face value of their life insurance policies:
through the life insurance company (accelerated death benefits), through a viatical company (a via tical settlement), or through a via tical loan company (a
via tical loan). This paper explores the definitions and tax regulations, calculations, and the claims process associated with accelerated death benefits and
via tical settlements and loans.
Key words and phrases: life expectancy, claims, taxes, regulations

1 Introduction
For a person diagnosed with a terminal illness, there are few monetary options available to pay the expenses needed to sustain his or
her life. Medical insurance may only cover expenses up to a limit, and
their savings and/or possessions may not be enough to cover bills. For
the insured terminally ill, however, there are often three other options:
accelerated death benefits, viatical settlements, or via tical loans.
*Paula Schmidt works in the priCing/product development department at Lincoln
Benefit Life Company. She completed her B.S. degree in actuarial science in 1995 from
the University of Nebraska-Lincoln and is currently working toward her associateship
and eventual fellowship in the Society of Actuaries. This is her first published work.
Ms. Schmidt's address is: Lincoln Benefit Life, PO Box 80469, Lincoln NE 68501-0469,
USA. Internet address: schmipat@allstate.com
tThis paper is based on the honors thesis that Ms. Schmidt completed for her B.Sc.
degree in actuarial science at the University of Nebraska-Lincoln. She is grateful for
comments from an anonymous referee, the editor, and Mr. Daniel Kahan, A.I.A., A.S.A.
of Canadian Life Line.
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Accelerated death benefits are benefits offered by life insurance companies to terminally ill insureds. The proceeds from an acceleration
result from a recalculation of the insured's life expectancy due to the
terminal illness and can be excluded from the owner's personal gross
income under current tax law. The proceeds consist of a fraction (typically 50 percent, but can vary from 25 percent to 100 percent depending
on the company) of the policy's face value, the remainder being paid at
the time of death. There is sometimes a waiver of premiums during the
period the insured is expected to die. If the insured survives the period,
there may be a resumption of premiums. Whether the premium needs
to be resumed is company specific and is stated in the policy or rider
form that contains the accelerated benefit provision.
The risk insurance companies take when they fund accelerated death
benefits differs from the risk insurance companies assume at the sale
of a life insurance policy. There is minimal adverse mortality risk involved in accelerated death benefits, if the physician's diagnosis is correct, given the likelihood of death occurring in the near future. Thus,
the risk assumed is primarily an investment risk.
A viatical settlement is one in which the owner of a life insurance
policy sells the policy to a viatical company for an amount less than the
face amount. The amount paid is directly related to the amount of time
the insured is expected to live, Le., the longer the life expectancy, the
less the amount paid. The viatical company in turn pays the remaining
premiums needed to keep the policy in force.
If the person lives longer than expected, viatical settlement companies will suffer a decrease in their investment return. Thus, viaticals
risk losing some of their profit. If they are highly leveraged, this could
be a large percent of that profit.
A viatical loan involves a policyowner giving collateral assignment
of his or her life insurance policy to a viaticalloan company. The loan is
then repaid in full at the time of death of the insured. The premiums are
paid by the viaticalloan company and are subtracted from the viatical
loan amount in the initial computation. Often, a via tical loan allows the
policyowner to receive more of the death benefit than an accelerated
death benefit or viatical settlement. At the death of the insured, the
balance of the death benefit is paid to beneficiaries.
The benefit covered in this paper is the terminal illness-triggered
benefit. To be eligible for this benefit, a physician must certify that
death is imminent within a specified time period. This time period is
usually six months to a year, though 24 months is the requirement in the
Internal Revenue Code for a benefit to be treated in a manner similar to
life insurance proceeds. Therefore, a terminal illness-triggered benefit
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is any payment made from a life insurance policy while the insured is
alive that results from recalculating the insured's life expectancy due
to the terminal illness.

2
2.1

Life Insurance Companies
The Calcu lation of Accelerated Death Benefits

There are two common methods used to calculate accelerated death
benefits: discounting the face value (less any outstanding policy loans)
of the policy or by taking a lien against the policy. Other methods are
used, but they are not as acceptable to most life insurance companies.
The discounting method requires the face value of the policy to be
discounted by a factor related to current market rates (e.g., the u.s. Treasury bill rate) and the length of the acceleration period. The amount
paid is subtracted from the face amount of the policy, which results in
a lower remaining death benefit. In some cases, companies waive the
premium during acceleration. Some life insurance companies charge an
administrative fee to cover the expenses of processing the acceleration.
Typical fees range from $100 to $300.
A simple example of discounting an accelerated death benefit follows. Assume a policy with a $100,000 face amount, a 60 percent acceleration benefit, no loans, a company-implemented administrative fee
of $200, and a Treasury bill rate of 8 percent. The insured is assumed to
have a year to live. The amount to cover the interest on the accelerated
portion is:
$60,000 - ($60,000/1.08) = $4,444.44.
Therefore the accelerated payment is:
$60,000 - $200 - $4,444.44

=

$55,355.56.

The policy would remain in force with a $40,000 death benefit.
In the lien method, the accelerated benefit is treated as a loan secured by the policy. Once death occurs, the loan is reimbursed with
interest from the entire death benefit. The difference between the lien
method and a straight policy loan is that for the lien method, advances
can exceed the contract's cash value. With a loan, however, the policyowner only is able to obtain an amount not higher than the cash value
of the policy.
Let us now look at a lien method example using the same scenario as
for discounting, with the exception that the 8 percent Treasury bill rate
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is assumed to be the loan rate and there is a $200 administrative fee.
The policyowner would be loaned $59,800 ($60,000 - $200) now. The
death benefit remaining, assumed to be paid in one year's time, would
be:
$100,000 - ($60,000 1.08) = $35,200.

*

The difference between the total payments for the two methods is
minimal (less than $400). With the discounting method a payment of
$55,355.56 could be received now and $40,000 at death. The total payment would be $95,355.56. The lien method offers $59,800 now and
$35,200 at death, a total of $95,000. The final deciding factors depend
upon the options available from the individual's insurance company.
Some companies only offer one of the options. The policyowner also
must decide if he or she would benefit from more money at acceleration
or at death. These decisions vary for each individual.

2.2

Regulations and Tax Treatment of Life Insurance Proceeds

When an accelerated death benefit is paid to a policyowner, the insurance company must send a statement illustrating the effect of the
benefit on the face amount of the policy, the specified amount of the
benefit, the accumulation account, the cash value, any loan balance, and
what the future premiums (if any) will be (Adam, 1990).
The National Association of Insurance Commissioners (NAIC) formulated model insurance regulations to serve as a guide to accelerated
death benefits. A disclosure required by the NAIC guideline l is a brief
description of the benefit and definitions of the conditions or occurrences that triggered the benefit payment. No further conditions may
be placed on the payment of accelerated benefits other than those specified initially in the policy or rider.
Benefit payment options also are covered in the NAIC 1996 guideline. The insured has the option of receiving the accelerated benefit
in a lump sum, in periodic payments for a fixed time, or in a fixed
amount for an indefinite period of time. Some companies require that
the accelerated benefit be taken as a lump sum, but most accommodate policyholder wishes. To receive the accelerated death benefit, the
owner often is required by the insurance company to surrender all or
part of his or her policyholder rights (Cruise, 1994).
1 NAIC guidelines can be obtained by writing to the NAIC at: NAIC, 120 West 12th
Street, Suite 1100, Kansas City MO 64105-1925, USA.
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The introduction of accelerated death benefits in early 1990 resulted
in the general public and some insurance companies being concerned
about tax uncertainties and terminology. To alleviate these concerns,
the Internal Revenue Service (IRS) and the NAIC established tax regulations and model insurance regulations, respectively. On August 21,
1996, President Clinton signed The Health Coverage Availability and
Affordability Act of 1996 (HR 3101) clarifying the tax treatment of accelerated death benefits. This act went into effect on January 1, 1997;
(see Chodes, 1997). The sections of the Internal Revenue Code (IRC)
that affect accelerated death benefits are Sections 72, 101, 7702, and
7702A. The regulations are being amended; more changes may occur
in the future.
State-specific regulations are based upon model regulations enacted
by the NAIC. The NAIC cannot force states or insurance companies to
use model regulations. Because the NAIC is composed of each state's
respective insurance commissioner, though, most states have adopted
the regulations.
Once the states accept regulations, insurance companies must comply and alter their poliCies (if needed) in order to do business within
each individual state. At first most states allowed accelerated death
benefit recipients to be exempt from state income taxes, though recipients may still have had to pay federal taxes (Blake, 1993). Because nobody really knew if taxes were owed or not, the NAIC advised insurance
companies to add a disclaimer suggesting the policyholder consult his
or her tax advisor about the tax treatment of such a provision (Adam,
1990).
Under Section 7702 of the IRC, a life insurance contract is defined as
any contract that is a life insurance contract under applicable law, but
only if the contract meets the cash value accumulation test or meets the
guideline premium requirement and falls within the cash value corridor.
Whichever of these two tests a life insurance contract meets at inception also must be met after a change in the death benefit is recorded
(Kraus, 1993). Therefore, a redetermination of values must occur after
accelera tion.
The tax treatment has always been a concern for those terminally
ill and considering such benefits. Current regulations provide that accelerated benefits will be considered as death benefits under Sections
101(a) and 7702. Section 101 states that any amount of a death benefit
received in a lump sum or otherwise paid by reason of death of the
insured is not included in a person's gross income (Freeman and Marcus, 1993). The Health Insurance Portability and Accountability Act of
1996 redefined Section 101 (g). With its passage there are now two types

110

Journal of Actuarial Practice, Vol. 5, No.1, 1997

of accelerated death benefits (received after December 31, 1996) that
are excludable from gross income. They are amounts received from
a life insurance policy or from a viatical settlement company for the
sale or assignment of a policy. The determining factor is that the insured is terminally or chronically ill (Wolosky, 1996). The act defines
being terminally ill as having 24 months or less to live. To be classed
as chronically ill, the insured is not able to perform at least two of six
listed daily activities (Christopher, 1997). This paper, however, will not
cover chronic illness benefits in any depth.
The definitions and regulations of the IRS and NAIC aim to clarify the treatment of accelerated benefits. Most state insurance departments have adopted similar regulations, so the alterations necessary
from state to state tend to be minimal. It is most probable that the tax
laws and regulations will continue to change as the insurance industry
becomes more experienced in accelerated benefits. For now, the proceeds from a qualifying acceleration can be received free from personal
income tax. With this clarification, the insurance industry should notice more terminally ill persons submitting claims for accelerated death
benefits.

2.3 The Claims Process for Accelerated Death Benefits
The process for accelerating the payment of benefits on a life policy
has many elements. Most companies require a minimum face amount to
be carried on a policy, i.e., $100,000, before any claim for acceleration
of the death benefit can occur. Fraudulent claims can be reduced by
setting a limit to the amount of accelerated benefit a policyholder can
receive. A minimum amount also may be set to avoid the relatively
excessive administrative expenses in processing small claims.
Specialized claim forms are required for acceleration. These forms
must be comprehensive enough to encompass all aspects of the illness
and the benefit payout. In addition, these forms should include verification and certification from the insured's physician stating the date of
diagnosis of the terminal illness, the extent of the insured's symptoms,
the proposed treatments and their efficacy, and the expected life span
of the insured. The insured also should be asked to complete a claim
form to prevent fraud (Adam, 1990).
When claims are made during the contestable period, special effort
must be made to determine whether the illness was present at the inception of the policy (Hitzeman, 1992). If the illness was present, it
gives the insurance company a legal reason not to accelerate the death
benefit. The insurer must verify that the policy is a valid contract and
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was issued based upon correct and accurate information before it determines whether the accelerated benefit is payable.
The medical information required by the claim forms should provide
adequate data for an initial investigation for the possible contestability
of the payment. If the submitted information appears to be legitimate
and satisfactory to the insurance company's medical board, the claim
is processed and paid (Reimers, 1994).
If the information appears to be false, an extensive investigation
usually follows. Certain steps are recommended to protect insurance
companies from fraud by policyholders and physicians. First, companies must verify the attending physician's credentials. The next step is
to obtain treatment records from any attending physicians and hospitals. It also may be beneficial to interview the insured and/or spouse to
determine the extent and severity of the illness and to rule out the possibility of self-inflicted injuries as the cause of the terminal condition.
The policyholder must be asked if he or she is mentally competent and
be determined as such (Hitzeman, 1992). Anything that seems suspicious should be investigated to safeguard the insurance company.
The insurance company should reserve its right to reaffirm the diagnosis of terminal illness by the company's medical doctor. Most companies also state within their rider or policy that if the insured's physician
disagrees with the company's physician on the diagnosis, the company
will pay a third impartial physician to perform an evaluation. Both
parties should agree the third diagnOSis will be the one by which the
insured and the company will abide (Hitzeman, 1992).
Because claims only can be made by the policyowner, irrevocable
beneficiaries and assignees can complicate the claim process. If a release cannot be obtained from either of these two, payment of the advanced benefit should be refused (Adam, 1990). In most cases the beneficiaries are close to the insured and are aware of the ramifications of
acceleration. Irrevocable beneficiaries and assignees commonly playa
large role in the decision to accelerate.
Companies offering such riders must be fair to all parties so they are
not accused of taking advantage of the insured and the terminal condition. At the same time the company must make correct assumptions
about the premiums and/or fees charged so that they do not lose money
offering such a benefit. Discrimination must not exist in the underwriting and processing of different types of terminal illnesses (Adam, 1990).
The insurance company also must protect the privacy of the insured.
No matter how careful and methodical an insurance company is in
investigating claims, problems will arise. One problem is how to deal
with an insured who recovers after receiving the accelerated death ben-
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efit. A correctly written policy should protect both parties in such an
event (Adam, 1990). Some companies require an insured to resume
payment of premiums on the face amount remaining after acceleration
if the insured survives beyond the acceleration period (Aerts, 1994).
Other companies waive the premium.
Another possible problem is an insured who commits suicide after
receiving his or her accelerated death benefit. If the suicide occurs
within the customary two year contestability period the policy would be
terminated; beneficiaries may have to repay the advance (Adam, 1990).
If suicide occurs after the contestable period beneficiaries may receive
the remaining death benefit. Each company must decide its stand on
suicides.
Claims practices of insurance companies are complicated by accelerated death benefits. In the past an insured died and a benefit was
paid. Now an insured may have a terminal illness, and a partial benefit may be paid. Insurance companies should expect more claims in a
wider variety and greater volume due to terminal conditions.
Accelerated death benefits are consumer friendly and possess a humanitarian appeal that complements traditional life insurance (Wang,
1990). This benefit promises an extra measure of financial security in
the event of a catastrophic or terminal illness. Life insurance products
have come to offer more while persons are alive instead of after they
have died. Accelerated death benefits are one way companies are offering their policyholders additional safeguards and personal benefits.
This benefit allows companies a slight marketing advantage. Accelerated benefits give the company's agents a selling point that is visible
and desirable for insureds. It is seen by some agents to be a low risk,
but a low reward provision.
Although some controversy surrounds accelerated death benefits,
most persons familiar with the concept praise it. The benefit may be received as a lump sum, in installments, or as expenses are incurred. Payment depends upon the insurance company and its established practices. The payment can be a way for a dying person to take care of
medical bills, visit family in a different part of the world, or do what
he or she always has dreamed. The adverse impact of an accelerated
death benefit is the decrease in the death benefit of the policy to the
insured's survivors.
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3 Viatical Companies
3.1

Viatical Settlements

There is a second option available to an insured whose insurance
company does not offer accelerated death benefits or to an insured who
wants an advance payment sooner than the insurance company offers.
This option is to sell the life insurance policy to a viatical company.
A viatical settlement is a private transaction in which a policyowner
sells the policy while the insured is living. The owner sells the policy
to a viatical company for an amount less than the face value of the
policy. Viaticals usually offer a contract under which the company is
designated as the sole benefiCiary of the life insurance policy. Most of
these contracts are made with insureds who are terminally ill or have a
catastrophic illness. Via tical companies expect to make their profits by
buying life insurance policies from terminally ill insureds.
The factors that determine the purchase price (Le., the amount of
payment offered) are based on the amount of the policy's death benefit,
the terminally ill insured's life expectancy, the annual premium, the
type of policy, the rating of the insurance company, and the market
rate available on a similar investment. Some companies may buy partial
benefits in which the policyholder names a co-benefiCiary who retains
an interest in the death benefit.
The purchase price, however, hinges on life expectancy-the more
time a person has to live, the less money the policyowner will receive
(Kristof, 1991). The key is evaluating an insured's life expectancy (Barrett, 1992). The sooner the insured dies, the sooner the viatical company receives the death benefit and its profit. This may sound inhumane [some have called viatical settlements death futures (Niedzielski,
1995)], but those selling the poliCies see the viatical option as a chance
to do something with part of the death benefit (Sing, 1990).
The policy sale process starts when the viatical company verifies
the life expectancy of the insured and computes a purchase price. The
owner can accept or reject the offer. If the policyowner rejects the
viatical company's initial purchase price, the viatical company often
returns to its investors and tries to improve its offer to one that is
more acceptable to the policyowner. Viatical companies are third-party
competitors in the free market. They try to offer the best possible price
to policyowners (Faig, 1997).
After buying the policy, the viatical company assumes the premium
payment and either becomes the sole beneficiary or a co-beneficiary of
the policy. At the time of death of the insured the viatical company
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collects the portion of the death benefit to which it is entitled. Thus
via tical companies require a large amount of upfront capital and have
no immediate payoff.

3.2

Regulations and Tax Treatment of Viatical Settlement
Proceeds

The via tical industry began in 1989 with three companies. Currently
there are 54 viatical settlement companies operating nationwide (Connolly, 1995b). The entire viatical industry is estimated to have had a
market of $400 million in policies purchased in 1994 and $500 million
in 1995, with the potential to reach $6 billion within the next five years
(Connolly, 1995a). As an industry they have established themselves as
an organized secondary market in the life insurance arena (Faig, 1997).
A growing concern is whether state insurance departments should
regulate viatical companies. Although viaticals are not insurance companies, they cross into the realm of the insurance industry. They are
purchasing policies involving mortality risk. A viatical company has the
option and ability to pay persons who have up to five years to live (which
is the void in the insurance industry that viatical companies fill) (Stone,
1993). Only settlements based on two years or less life expectancy,
however, could be received tax free.
The Health Insurance Portability and Accountability Act of 1996 now
defines terminally ill as having 24 months or less to live. A stipulation in
the 1996 act is that in order for a viatical settlement to be considered
to be tax-free, the viatical company must be licensed by the state. If
that state does not have a licensing system the viatical must pay to the
policyowner at least the minimum in purchase price (see Table 1) for
policies as set by the NAIC viatical model act. The regulations do allow
viaticals to decide the length of life expectancy in which they will invest
and if they will pay more than these minimum required prices.
The percentages in Table 1 may be reduced 5 percent for viaticating
a policy written by an insurer rated less than the highest four categories by A.M. Best. This percentage reduction could be alleviated by
the existence of state guarantee associations which would lessen the
bankruptcy risk of the less favorably rated companies.
Though the number of persons wanting to sell their life insurance
policies to viaticals is relatively low, it continues to rise each year. Limits
to acceleration and the possibility for a high return mean that investors
are eager to buy viator policies. Insurance regulators and insurance
companies are concerned, however, that viatical companies may become a problem for the insurance industry. Moral risk has been cited
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Table 1
NAIC Model Minimum Pur cha se Pric
e
As a Per cen tag e of Policy Face Val
ue
Life Expectancy Months
Minimum
(In Months)
Percentage
<6

6-12
12- 18
18- 24
24+

80%
70%

65%
60%

50%

as a major factor in the regulation
of via tical companies. It has bee n
considered by som e tha t the via tica
l ind ustr y has bee n cre ated by com
panies waiting for a financial rew
ard tha t is greatly inc rea sed by the
early dea th of an insu red (Faig, 199
7).
Via tical companies ten d to believe
they are dealing with the sale of
a private ass et tha t sho uld not con
cern the NAIC. The viatical ind ust ry
also was und er atta ck by the Securit
ies and Exchange Commission (SEC
)
from August 1995 unt il July 1996.
The SEC con side red viatical settlemen ts to be securities and challen
ged their validity in the U.S. cou rt
sys tem (Connolly, 1995a). The SEC
wanted viaticals to reg iste r the frac
tionalized shares of life insurance poli
ces they were selling to investors.
Many of the via tical sett lem ent com
panies disliked this bec aus e it infringed on the small investors who
could only afford to pur cha se sha res
of policies and not entire ones.
The District of Columbia Court of
Appeals rule d in July 1996 tha t
viatical sett lem ent s are not securit
ies and are not to be con side red insur anc e policies either (Connolly,
1996). The cou rt held tha t "... a viatical sett lem ent is not an insurance
policy, and the bus ine ss of selling
fractional inte rest s in insu ran ce poli
cies is no par t of the bus ine ss of
insurance" (Connolly, 1996). The cou
rt rea son ed tha t profits from suc h
viatical sett lem ent s do not come from
the efforts of a par ty oth er tha n
the investors themselves. The SEC
may appeal this ruling.
The via ticals see the legislation and
regulations as hin dra nce s to
their business. Regulation also may
affect the selling price of policies.
With increased costs due to registr
ation fees and expenses inc urre d
bec aus e of req uire d compliance, the
amo unt an insu red would receive
would decrease. In the end, legislat
ion and regulations could hur t the
per son s regulators are trying to help
.
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companies, viaticals, and the general public) will lead to more stability
in the accelerated benefits industry.
Medical advances will be a significant factor in the future of accelerated death benefits for many reasons. First, with further developments
and enhancements of DNA and genetic testing, the diagnosis of the possibility of being stricken with a terminal illness at some point of time in
the future will become more accurate. Second, the enhanced treatment
of and/or cures for current diseases will reduce the severity of terminal
illness. These two reasons may make the calculation of life expectancies more difficult, however, as has been the example of AIDS protease
inhibitors. These inhibitors have greatly increase the life expectancy
of some patients while they have not had much of an effect on others.
Even though these are beneficial advances, such new-found methods
may cause uncertainty among those calculating life expectancies.
Eventually, increased accuracy in calculating life expectancy and
more readily available advanced treatment methods will lead to more
exact accelerated death benefit payments. The final payout, however,
will be based on who calculates the life expectancy, what formula is
used, and who has made the final terminal diagnosis. When the final
payout is made because of decisions of a handful of persons, the result
can make or break a terminally ill insured and could be construed as
morally unjust. Using a simple equation may allow difficult decisions
to be minimized by simplistic assumptions for mortality and interest.
If the time between payout and death can be determined, the dollar
investment necessary to cover the difference between the accelerated
portion and the actual will be more accurately calculated. This is an
advantage to all parties and would reduce the risk and profit margins.
Not only can the insurance and viatical companies cover any losses
while also making a profit, but insureds also should receive the best
price for the policy.
The path of accelerated death benefits and viatical settlement companies will continue in the same direction, but the company field will
narrow. Only those viaticals that are strong in their investment portfolios and keep up to date with medical advances will remain in the
accelerated death benefit market. In the future viaticals also may buy
life insurance policies from healthy but old persons.
Steven Arenson, a vice president of Viaticus, Inc., painted a picture
of the current viatical market. In Employee Benefit Plan Review (1996)
Mr. Arenson was quoted as saying, "Only 2% of the terminally ill are
AIDS patients, but 95% of those early viatical settlements (mid-1980's)
involved AIDS victims. Last year (1995), 23% of our viatical settlements
involved cancer patients." This represents the shift in the viatical mar-
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ket from one almost entirely serving AIDS patients to expanding to
other illnesses.
Some of the unsettled issues are:
• Whether the use of the accelerated benefit proceeds can be restricted (Pear, 1992); What happens if the insured lives longer than
the stipulated length for the acceleration; and
• What effects the accelerated benefits will have on a person's eligibility for governmental assistance (Will it be considered an asset?)
(Employee Benefit Plan Review, 1990).

Additional questions arise from beneficiaries over estate tax and estate/inheritance tax treatment of the death benefit remaining after acceleration. Because of these and other issues, some insurance companies have been waiting to initiate and introduce accelerated benefits.
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